ProPharma has been recognized as a dual-category winner in the Clinical Trial Arena Excellence Awards, receiving accolades in both Business Expansion and Mergers & Acquisitions (M&A). These awards highlight the significant achievements stemming from the acquisition of Clinres Farmacija, a Croatia-based contract research organization (CRO), which has bolstered clinical trial capabilities and expanded reach into Central and Eastern Europe.
The Clinical Trials Arena Excellence Awards, powered by the business intelligence of GlobalData, recognize the outstanding achievements and innovations that are propelling the industry forward.
ProPharma's recognition in Business Expansion highlights its successful foray into the Central Eastern European market, while the M&A award acknowledges the seamless integration of Clinres Farmacija's expertise, which has enhanced ProPharma's global service offerings and solidified its commitment to innovation and regulatory excellence.
Enhancing clinical research services and reach
The strategic acquisition of Clinres Farmacija has enabled ProPharma to enhance its clinical trial capabilities significantly and extend its reach into the Central Eastern European market.
Clinres Farmacija's two decades of experience and robust portfolio of over 250 clinical studies have enriched ProPharma's operations, positioning the company as a frontrunner in the life sciences sector and providing a foothold in the broader European market, where the demand for cost-effective and high-quality clinical services continues to grow.
With Clinres Farmacija's established presence and regional expertise in South-east Europe, ProPharma has gained access to a significant talent pool and expertise in pharmaceutical development. The acquisition has further solidified ProPharma's position as the world’s largest Research Consulting Organization (RCO) by strategically expanding its global footprint to deliver innovative services and solutions to its valued client partners.
Comprehensive solutions for evolving client needs
With the acquisition, ProPharma now offers an expanded suite of services that spans the entire range of clinical trial phases, from Phase 1b to Phase 4. The comprehensive services include site management, international project management, medical writing, and drug depot validation.
Additionally, Clinres Farmacija's capabilities in legal representation, translation services, feasibility studies, site activation and contracting, Ethics Committee (EC) and Regulatory Authority (RA) submissions, and regulatory intelligence have been integrated into ProPharma's offerings.
The expansion ensures ProPharma can address a broader spectrum of client needs, fostering the development of innovative therapies and contributing to healthier patient outcomes. The combined expertise ensures that clients benefit from a seamless experience, tailored to their clinical and regulatory requirements.
Driving innovation and healthier outcomes
ProPharma's dedication to innovation and healthier outcomes has been the driving force behind its acquisition strategy. By incorporating Clinres Farmacija's capabilities, ProPharma is better equipped to meet the evolving needs of the life sciences industry.
Its strengthened presence in Central and Eastern Europe offers a competitive edge, facilitating the advancement of pharmaceutical, medical device, and diagnostic development programs.
Clinres Farmacija's team of Regulatory Affairs professionals with extensive experience across the full range of regulatory procedures, including the submission of marketing authorization applications and post-approval support, enhances ProPharma's ability to ensure high-quality compliance and on-time delivery of services.
“We are honored to be recognized as a leader in both Business Expansion and Mergers & Acquisitions by the Clinical Trial Arena Excellence Awards. This achievement underscores our commitment to delivering innovative solutions and expanding our global reach, which was significantly enhanced by the acquisition of Clinres Farmacija. By integrating their expertise and extensive experience, we continue to strengthen our clinical trial capabilities and regulatory services, ensuring excellence for our clients while advancing life-saving therapies and improving patient health and safety worldwide.” - Jason DeGoes, President ProPharma
